Home
>
National Drug Code (NDC)
>
NULOJIX
NULOJIX - 0003-0371-13 - (BELATACEPT)
Drug Information of NULOJIX
| Product NDC: | 0003-0371 |
| Proprietary Name: | NULOJIX |
| Non Proprietary Name: | BELATACEPT |
| Active Ingredient(s): | 250 mg/1 & nbsp; BELATACEPT |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of NULOJIX
| Product NDC: | 0003-0371 |
| Labeler Name: | E.R. Squibb & Sons, L.L.C. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA125288 |
| Marketing Category: | BLA |
| Start Marketing Date: | 20110615 |
Package Information of NULOJIX
| Package NDC: | 0003-0371-13 |
| Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (0003-0371-13) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE |
NDC Information of NULOJIX
| NDC Code | 0003-0371-13 |
| Proprietary Name | NULOJIX |
| Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (0003-0371-13) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE |
| Product NDC | 0003-0371 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | BELATACEPT |
| Dosage Form Name | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20110615 |
| Marketing Category Name | BLA |
| Labeler Name | E.R. Squibb & Sons, L.L.C. |
| Substance Name | BELATACEPT |
| Strength Number | 250 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | T Lymphocyte Costimulation Activity Blockade [PE],Selective T Cell Costimulation Blocker [EPC],CD80-directed Antibody Interactions [MoA],CD86-directed Antibody Interactions [MoA] |
